Results 151 to 160 of about 115,959 (294)

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

Cancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

A giant serous papillary cystadenofibroma mimicking a bladder tumor: A diagnostic pitfall. [PDF]

Urol Case Rep
Eyüp Ö, Koçoğlu F, Balıkçı A, Koncuk MS.   +3 more
europepmc   +1 more source

UBE2C‐Mediated CD147‐CTLA‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer

Cancer Science, EarlyView.
UBE2C upregulates cellular CD147 and enhances its release into the tumor microenvironment both as soluble CD147 (sCD147) and packaged within tumor‐derived exosomes. These CD147‐bearing signals induce T‐cell exhaustion, marked by elevated CTLA‐4 expression and reduced secretion of effector cytokines (IFN‐γ, TNF‐α, TGF‐β), ultimately diminishing CD8+ T ...
Xuwei Hong, Ting Hong, Xinyu Liu, Peixiu Yao, Weiqiang Lin, Guoyuan Liu, Huihong Guan, Yonghai Zhang   +7 more
wiley   +1 more source

Leiomyoma: a case of a rare benign mesenchymal neoplasm of the urinary bladder

Polish Archives of Internal Medicine, 2022
Balawender, Krzysztof, Wawrzyniak, Agata, Walocha, Jerzy, Mazur, Małgorzata, Żytkowski, Andrzej, Wysiadecki, Grzegorz   +5 more
openaire   +3 more sources

Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers

Cancer Science, EarlyView.
Experimental BBN models link gut microbial metabolism and diet‐microbiome interactions to urothelial carcinogenesis, while circulating extracellular vesicle‐associated bacterial DNA signals may reflect tumor immune contexture and immune checkpoint inhibitor outcomes in urothelial and renal cell carcinoma.
Atsunari Kawashima, Kentaro Jingushi, Takuro Saito, Toshihiro Uemura, Akinaru Yamamoto, Nesrine Sassi, Hiromu Horitani, Shunsuke Inoguchi, Yuki Horibe, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Norio Nonomura   +12 more
wiley   +1 more source

Tubular adenoma of the urinary bladder in a female patient: An extremely rare entity clinically mimicking urothelial malignancy. [PDF]

Urol Case Rep
Taşpınar C, Sabuncu A, Duman Kurt E, Paşaoğlu HE, Kandıralı İE, Özsoy Ş.   +5 more
europepmc   +1 more source

Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non‐Invasive Diagnosis of Bladder Cancer

Cancer Science, EarlyView.
Clinical application scenarios for the diagnosis of BC. A schematic diagram illustrating the use of sEV DNA liquid biopsy technology to differentiate between benign and bladder cancer patients. ABSTRACT Existing diagnostic technologies for bladder cancer (BC) suffer from low sensitivity, low specificity, or a lack of validation.
Tao Wang, Xin Liao, Jiyang Zhang, Xiaoya Xu, Wei Zhang, Xinlin Chen, Xinyu Zhai, Tongtong Zhang, Xiangyang Zhan, Xingyu Mu, Dadong Zhang, Jian Chen, Dongliang Xu, Mingyue Tan   +13 more
wiley   +1 more source

Urinary bladder invasion secondary to dissemination of gallbladder cancer: an unusual presentation. [PDF]

Clin J Gastroenterol
Watanabe R, Koshitani T, Hashidume S, Kasho K, Yokomura A, Takihara H, Takemoto T, Itoh M, Nakajima N.   +8 more
europepmc   +1 more source

Extraperitoneal single‐site robot‐assisted radical prostatectomy with extended pelvic lymph node dissection: technique and experience

BJU International, Volume 135, Issue 4, Page 700-705, April 2025.
Yubo Wang, Mingzhao Li, Kai Yao, Zhuyinjun Zong, Yifan Chang, Yongda Liu, Chao Cai, Fadi Mousa Al Kalailah, Shancheng Ren, Guohua Zeng, Di Gu   +10 more
wiley   +1 more source

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

Cancer Science, EarlyView.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, Satoshi Nishiwaki, Ichiro Kinoshita, Tetsuhiro Yoshinami, Chigusa Morizane, Yusuke Sato, Toshio Kubo, Mamoru Ito, Hiroshi Nishihara, Toru Mukohara, Hidekazu Shirota, Ryo Ko, Taro Shibata, Manabu Muto, Noboru Yamamoto   +16 more
wiley   +1 more source